TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Home Usability of a Nasal Lavage System in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Parents of children less than 6 years of age who were suffering from nasal congestion for which nasal suctioning and salt water irrigation/drops are prescribed.~Exclusion Criteria:~* Parents of children in marked respiratory distress or who maxillofacial malformations not conducive to nasal suctioning.~* Additionally, parents of children with recurrent nose bleeds, bleeding disorders or irritated peri-nasal skin were excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Parents of congested children (Type: None): Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Satisfaction of Limited English-Proficient Patients With Phone Interpretation Services Compared to In-Person Interpreters: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LEP speaking Spanish and Portuguese female patients presenting to the U Mass UROGYN clinic with or without Ad-hoc interpreters~* Spanish and Portuguese speaking female patients with LEP presenting to the U Mass UROGYN clinic for an office visit of any type~Exclusion Criteria:~* Unable to provide consent~* Under 18 years of age~* Pregnant women~* Prisoners~* LEP subjects who decline interpreter services~* Non -Spanish or Non - Portuguese speaking subjects~* Patients with cognitive impairment~* Visually or hearing impaired patients~* Patients not requiring a follow up appointment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interpretation Modality: In person (Type: ACTIVE_COMPARATOR): Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
- Interpretation Modality: Telephonic (Type: ACTIVE_COMPARATOR): Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Both gender ≥ 18 years old~* From Medium to High exuding wound~Exclusion Criteria:~* Known allergy or hypersensitivity to any of the treatment dressings~* Pregnant or lactating females~* Subjects with a target wound that is ≤1 cm2~* Subjects with a target wound that is a full thickness burn~* Subjects with a target wound that is a full thickness pressure ulcer~* Subjects with known immunodeficiency~* Subject taking systemic antibiotics for wound infection~* Subject were the target wound is located on an infected limb interfered by minimal blood flow in the opinion of the investigator~* Subject with a target wound with unexplored enteric fistula~* Subjects who in the opinion of the investigator, will have problems following the protocol~* Subjects needing treatment with oxidizing agents such as hypochlorite solutions or hydrogen peroxide~* Previously enrolled in the present investigation~* Inclusion in other ongoing investigations at present that would preclude the subject from participating in this investigation as judged by the investigator~* Involvement in the planning and conduct of the clinical investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exufiber Ag + (Type: OTHER): Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
- Exufiber (Type: OTHER): Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
- Aquacel® Ag Extra (Type: OTHER): Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Scleroderma ARFI Imaging of the Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Rheumatologic disease of the skin including: Limited Scleroderma, Diffuse Scleroderma, or Eosinophilic Fascitis (Schulman's Syndrome)~Exclusion Criteria:~1. None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ARFI-SVI Ultrasound (Type: None): Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
- Healthy Volunteers: ARFI/SVI Ultrasound (Type: None): Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder~* experiencing a current major depressive episode~* able to provide written informed consent~Major Exclusion Criteria:~* any female subject who is pregnant or breast-feeding~* any subject judged to be medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumateperone (Type: EXPERIMENTAL): Lumateperone 42 mg (ITI-007 60 mg tosylate) administered once daily every evening for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered once daily every evening for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have pathologically-confirmed, resectable, squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx~* Disease must be Stage I, II, III or IVa~* Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy~* Eastern Cooperative Oncology Group (ECOG) Performance status 0-2~* Patients must give documented informed consent to participate in this study~Exclusion Criteria:~* Documented evidence of distant metastases~* Ongoing acute medical condition such as uncontrolled coronary artery disease, emphysema, or diabetes mellitus that would preclude surgical resection~* Pregnancy or lactation; patients of child bearing age must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of soy administration~* A medical or psychiatric illness which would compromise the patient's ability to tolerate this treatment or comply with administration of study drug~* Patients residing in prison~* Any patient with a history of breast or ovarian cancer~* Allergy to soy products

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (soy isoflavones) (Type: EXPERIMENTAL): Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Structured Non-operative Treatment of Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Knee-OA detected by x-ray (Kellgren \& Lawrence grade 1 or greater)~* KOOS4 of ≤ 75~* Considered not to be a candidate for Total Knee Replacement (TKR) by the orthopedic surgeon.~* The participant is \> 18 years of age.~* The participant can provide relevant and adequate, informed consent.~Exclusion Criteria:~* Prior TKA ipsilateral~* Rheumatoid arthritis~* Mean VAS \> 60mm the last week on a 0-100mm scale~* Possible pregnancy or planning pregnancy;~* Inability to comply with the protocol;~* Inadequacy in written and spoken Danish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEDIC (Type: ACTIVE_COMPARATOR): Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
- Standard treatment (Type: ACTIVE_COMPARATOR): Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Post-bariatric surgery more than 6 months prior to signing the informed consent~* Reported history of Whipple's triad: the occurrence of hypoglycemic symptoms associated with a capillary blood glucose of ≤55 mg/dL, and resolution with glucose or carbohydrate administration.~* Symptomatic hypoglycemia during the baseline/screening oral glucose tolerance test (OGTT), as defined by the presence of plasma glucose ≤55 mg/dL with concomitant autonomic and/or neuroglycopenic symptoms.~Exclusion Criteria:~* Patients currently using sulfonylureas or other medications that may interfere with glucose metabolism within 5 half-lives of drug.~* Participation in any clinical investigation within 4 weeks prior to dosing~* History of or current insulinoma~* Active infection or significant acute illness within 2 weeks prior to dosing~* Female patients who are pregnant or lactating~* Women of childbearing potential and not utilizing effective contraceptive methods~* Inadequate end organ function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Lyo avexitide 0.05 mg/kg (Type: EXPERIMENTAL): Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
- Part A: Lyo avexitide 0.15 mg/kg (Type: EXPERIMENTAL): Participants will receive Lyo avexitide twice daily for 3 days
- Part A: Lyo avexitide 0.35 mg/kg (Type: EXPERIMENTAL): Participants will receive Lyo avexitide twice daily for 3 days
- Part A: Lyo avexitide 0.46 mg/kg (Type: EXPERIMENTAL): Participants will receive Lyo avexitide twice daily for 3 days
- Part B: Liq avexitide 0.38 (±0.03) mg/kg (Type: EXPERIMENTAL): Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients of more than 18 years of age~* Patients presenting with anemia following chemotherapy~* Patients suffer from solid tumours, malignant hemopathies, lymphomas or myelomas and presenting with anemia following chemotherapy~  -- The patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle)~* Patients eligible for epoetin alfa biosimilar treatment~Exclusion Criteria:~* Patients are not receiving chemotherapy~* Patients already included in an epoetin zeta trial~* Patients presenting with a contraindication to epoetin zeta~* Patients presenting with hypersensitivity to the active principle or any of the excipients~* Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA)~* Patient with uncontrollable arterial hypertension~* Patients who cannot receive adequate prophylaxis by antithrombotic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with chemo-induced symptomatic anemia (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regulatory Post-Marketing Surveillance Study for TETRAXIM™

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are 2 months or more of age (as indicated in the currently approved local product labeling) and who are given the study vaccine at least one dose or more, during a routine health-care visit, as primary immunization or booster immunization for the prevention of diphtheria, tetanus, pertussis, poliomyelitis.~* Written informed consent obtained from the subject's parents/legal representative.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- TETRAXIM™ vaccine (Type: EXPERIMENTAL): Participants will receive a primary or booster dose of TETRAXIM™

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria. Each patient must meet all the following criteria in order to participate in this trial:~1. Newly diagnosed and untreated children (only treatment with 1 NSAID is allowed and/or prednisone \>1 mg/kg/day for no more than 1 month from diagnosis) with probable or definite diagnosis of JDM according to published (12;13). If a muscle biopsy will be performed (optional) it will be read by the pathologists of the participating centres (light and immunofluorescence). Slides of paraffin-embedded sections from all patients will be re-viewed by a blinded myopathologist at PRINTO.~2. Age at enrolment ≤ 18 years.~3. Female of child-bearing potential must have a negative pregnancy test at the beginning of the trial, and then every 3 months. If sexually active, they must agree to use adequate contraception, throughout study participation, and must have no intention of conceiving during the course of the study. Post-pubertal males must have no plans to father a child during the study and agree to use adequate birth control methods if sexually active.~4. Ability to comply with the entire study procedures, ability to communicate meaningfully with the investigational staff, competence to give written informed consent; to be applied to the parents and/or patients, as appropriate~5. Duly executed, written, informed consent obtained from the parents/patient.~Exclusion Criteria. Any of the following will exclude a patient from this trial:~1. Neutrophil count \<1,500/mm3 and/or platelet count \<50,000/mm3~2. Demonstration of cutaneous or gastrointestinal ulceration of JDM related pulmonary disease or cardiomyopathy at the time of diagnosis.~3. History of poor compliance.~4. Evidence of current use of alcohol or illicit drugs abuse.~5. Live vaccines not allowed during the entire duration of the trial.~Dropout Criteria. Patients will be considered treatment failures, and dropped from the trial but included in efficacy analysis, if any of the following will occur during the active period of the trial.~1. Non compliance with study medication administration~2. Enrolment in other therapeutic trials.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone pulse (MPDN)+PDN+CSA (Type: ACTIVE_COMPARATOR): MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
- MPDN+PDN+MTX (Type: ACTIVE_COMPARATOR): MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
- MPDN+PDN (Type: ACTIVE_COMPARATOR): MPDN= methylprednisolone PDN= prednisone or equivalent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, locally unresectable or metastatic biliary tract or gallbladder adenocarcinoma. Patients must have at least one measurable lesion outside prior radiation field.~* Zero to one prior chemotherapy for biliary tract or gallbladder cancer~* Age \> 18 years~* ECOG performance status 0-2~* Life expectancy \> 12 weeks~* Adequate organ and bone marrow function~Exclusion Criteria:~* Chemotherapy within past 3 weeks of initiation of therapy~* Pregnant or lactating women~* Clinically apparent central nervous system metastases or carcinomatous meningitis~* Biliary obstruction with inadequate drainage and total bilirubin \> 2.5 mg/dL~* Concurrent malignancy of any site, except limited basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix~* Uncontrolled serious medical or psychiatric illness~* Pre-existing peripheral neuropathy of grade 2 or greater severity according to the Common Terminology Criteria of the NCI (version 3.0)~* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study~* Blood pressure of \> 150/100 mmHg~* Unstable angina~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction or stroke within 6 months~* Clinically significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Major surgical procedure, open biopsy, or significant traumatic injury with 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the study~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 1~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab, Gemcitabine, Oxaliplatin (Type: EXPERIMENTAL): * The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~* Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~* Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete